comparing neoadjuvant versus adjuvant regimens of anti–PD-1 plus anti–CTLA-4 found a greater expansion of tumor-resident T-cell clones in the peripheral blood of patients enrolled on the neoadjuvant arm (42). Here, CTLA4 is linked to neoplasm.